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Background and Rationale
Infectious diseases remain a major
health and socioeconomic problem in
many low-income countries, particularly
in sub-Saharan Africa. Most of the public
attention has so far been devoted to the
three most devastating diseases, HIV/
AIDS, malaria, and tuberculosis (TB).
However, in rural and impoverished
urban areas of low-income countries, a
number of neglected infectious diseases
(NIDs) cause massive suffering, although
they receive little or no scientific or mass-
media attention [1]. By considering all
NIDs together, it is obvious that they
threaten the health of the poorest to a
similar extent as the three major killers [2–
4]. It has been calculated that a group of
13 NIDs, including Buruli ulcer (Mycobac-
terium ulcerae), cholera (Vibrio cholerae), cys-
ticercosis, dracunculiasis (Guinea worm),
trematodal infections, hydatidosis, leish-
maniasis, lymphatic filariasis (elephantia-
sis), onchocerciasis (river blindness), schis-
tosomiasis, helminthiasis, trachoma
(Chlamidia trachomatis), and trypanosomiasis
(African sleeping sickness, Chagas disease),
affect over one billion people (correspond-
ing to a sixth of the world’s population)
[4]. For most of these diseases, vaccines
are either unavailable, ineffective, or too
expensive. Moreover, NIDs often occur in
individuals that are also affected by HIV/
AIDS, malaria, or TB, indicating that co-
infections are the rule rather than the
exception in many geographical areas [2–
5]. In order to develop effective vaccina-
tion and treatment strategies, it is essential
to understand how protective immunity to
a pathogen can be achieved in individuals
co-infected with multiple pathogens.
Amongst the numerous specific research
programmes launched by several national
and international organisations to under-
stand and confront the burden of HIV/
AIDS, malaria, and TB, little has been
done to specifically address the complex
issue of immunity during co-infections
with the three major killers and NIDs.
So far, it is mainly the European Com-
mission (EC) that has recognised the need
to pursue an active research policy for
developing new or improved prophylactics
and treatments for infectious diseases,
including new vaccines and drugs for
NIDs, keeping this research area alive in
the face of declining national support.
While the 6th Framework Programme
(FP6) of the EC mainly addressed transla-
tional research for HIV/AIDS, malaria,
and TB, the new 7th Framework Pro-
gramme (FP7, 2007–2013) will also in-
clude NIDs [6]. The new commitment to
NIDs in FP7 creates an unprecedented
opportunity to actively address the scien-
tific challenges associated with co-infec-
tions between HIV/AIDS, malaria, TB,
and NIDs. In addition, the Special Pro-
gramme for Research and Training in
Tropical Diseases of the World Health
Organization (WHO/TDR) has shown
renewed interest for translational research
in NIDs. The recently updated strategy of
WHO/TDR aims to support research on
neglected needs by fostering innovation for
product development, and for access to
interventions [7]. It is hoped that indus-
tries involved in vaccine and drug devel-
opment will acknowledge the new strate-
gies against NIDs of the European Union
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implementing research and development
activities against NIDs, in particular in the
area of immunological correlates of pro-
tection and vaccine development.
To address the increasing importance of
co-infections, scientists from 14 different
countries in Africa and Europe met in
Addis Ababa, Ethiopia, on September 9–
11, 2007, to identify and prioritise re-
search gaps in this area. The meeting was
convened by two ongoing EC-funded
initiatives, namely the MUVAPRED inte-
grated project and the BIOMALPAR
network of excellence, and gathered
high-level scientists, clinicians, and indus-
trial expertise, as well as representatives
from the EC and WHO/TDR. This
report summarises the consensus of the
expert group, which took the name of
AFRIEND (African-European Partnership
for Neglected Infectious Diseases). It is
envisaged that this document could foster
a debate in the scientific community and
provide recommendations on future ac-
tions by the EC and WHO/TDR in the
area of co-infections and NIDs.
Objectives
It is of key importance to focus future
research on a detailed understanding of
the mechanisms of immunity to pathogens
during co-infections between HIV/AIDS,
malaria, and TB, and NIDs. This infor-
mation will be highly relevant for the
development of new preventive and ther-
apeutic interventions for use in impover-
ished areas of disease-endemic countries.
Indeed, multiple infections, nutritional
status, and level of exposure to microbi-
al/parasitic compounds can alter the
reactivity of the immune system in such
a way that vaccines may need new/novel
formulations. Research priorities should
focus on immunological studies in hu-
mans, preceded and supported by exper-
imentation on suitable animal models, and
should include the following key areas.
Correlates of Protection
Identification of correlates of protection
is of major importance for the develop-
ment of new effective preventive/thera-
peutic strategies. Although some progress
has been made to identify correlates of
protection, much more intensive funding
and research are needed to tackle this
complex and central area of investigation.
Indeed, to date, no convincing correlates
of protection have been yet identified for
HIV/AIDS, malaria, TB, or NIDs.
As a general assumption, the main
correlates of protection in human infec-
tions are represented by the presence of
pathogen-specific effector cells/molecules
(CD8
+ and CD4
+ T cells, antibody-
producing B cells, neutralising antibodies).
More recently, it has become clear that
early triggering of innate immune mech-
anisms can also represent an important
determinant of protective immunity. As-
says to measure these immune responses
are expensive and technically demanding.
Therefore, in the search for reliable
correlates of protection, priority should
be given to the development of simplified,
standardised, and low-cost assays.
Mechanisms of Infection and
Immunity at Local Sites
The pathogens responsible for HIV/
AIDS, TB, and many of the NIDs invade
the human hosts at mucosal surfaces, which
act as a primary antimicrobial barrier
through non-specific and specific defence
mechanisms. In most cases, little attention
has been focused on the role of local
defences in the control of NIDs. Therefore,
the design of strategies to target the local
immune defences and to elicit an early
mucosal immune response will be crucial.
Immunological Memory
Immunity to HIV/AIDS, malaria, TB,
and NIDs appears to be short-lived,
possibly due to the impairment of memory
B and T cells and of long-lived plasma cells.
Only a few well-designed studies in
humans are available that detail the effects
of co-infection on the immune response,
but these indicate that important interac-
tions indeed take place that affect the
immune response to each of the infecting
organisms. For example, HIV infection in
primigravid women significantly reduces
antibody responses to several important
malaria antigens [8]. It is therefore crucial
to understand the effects of multiple
infections on adaptive immunity and the
establishment of immunological memory
to the individual pathogens.
Thus, efforts against HIV/AIDS, ma-
laria, TB, and NIDs should include studies
to characterise the profile of the memory
responses in naturally exposed popula-
tions, as well as development of assays to
measure memory phenotype and function.
Impact of Co-Infection on the
Outcome of HIV/AIDS, Malaria, TB,
and NIDs
More than one billion people worldwide
are infected with helminths. Such infec-
tions have been shown to cause a range of
effects on immune response, characterised
by enhanced T helper (Th) 2-type cytokine
profile, upregulated regulatory T cell
activity, and chronic immune activation.
All of these are factors that may have
adverse effects on the outcome of subse-
quent infections and vaccinations. In
support of this, studies conducted in
animals and humans living in worm-
endemic areas have shown that helminths
impair resistance against a number of
infections, including HIV/AIDS, malaria,
and TB [9–11]. Accordingly, mortality is
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from visceral leishmaniasis, while leprosy
seems to be unmasked in co-infected
patients when HIV immunosuppression
improves with HAART. Infection with
schistosomes makes people more suscepti-
ble to HIV infection by interfering with
immune responses or by increasing the risk
of transmission [10,12]. The interaction
between worms and malaria is extremely
complex, as people suffering from worm
infection and malaria can have higher
incidence but reduced severity, while
transmission is apparently increased
[10,11]. In sub-Saharan Africa, over
75% of cases of TB are HIV-associated
[12]. TB is the leading cause of AIDS-
related deaths in low-income countries,
and it has been shown that HIV infection
increases the risk of progression of TB
infection, reactivation of latent infection,
and the fatality rate. Other examples of
interactions between infections include the
interaction between Epstein–Barr virus
and malaria, which has been known for
many years [13], and HIV and herpes
simplex viruses [14]. However, the degree
to which this balance is perfected, and the
mechanisms by which this is achieved, is
far from clear. To understand these
complex interactions better, well-designed,
controlled intervention studies are needed
that could allow us to clarify the mecha-
nisms of protection and to design effective
prophylactic and/or therapeutic strategies.
Research in this direction is therefore of
key importance and should be strongly
supported.
Impact of Non-Infectious Agents on
the Outcome of HIV/AIDS, Malaria,
TB, and NIDs
Infections in poor communities occur in
a setting where the population is exposed
to several environmental and social con-
ditions that could influence the immune
response to pathogens. These include
chronic hunger, micronutrient deficiency,
multiple pregnancies, etc. Although the
relationship between nutrition and immu-
nity is complex, it is clearly established that
nutrient deficiencies can severely impair
the immune response. Studies in animal
models show an association between
malnourishment and disseminated disease
development after Leishmania infection.
However, the complexity of the issue is
underlined by the notion that iron defi-
ciency and malnourishment can protect
children against severe malaria [15].
Therefore, it becomes essential to investi-
gate and document the basal immunolog-
ical parameters in a given population, and
to determine the ‘‘normal values’’ or
reference ranges for the particular popu-
lation in the endemic set up.
Host Genetics and Outcome of HIV/
AIDS, Malaria, TB, and NIDs
The role of genetic differences in the
susceptibility of African populations to
HIV/AIDS, malaria, TB, and NIDs has
not yet been extensively studied. The
significance of host genetic background
in disease outcome can be exemplified by
the well-known protective effect of the
sickle cell trait against malaria in Africa. A
number of reports have demonstrated the
role of chemokine receptor variants in
preventing, delaying, or accelerating pro-
gression of HIV infection to AIDS [16].
Similarly, host genetic factors such as
HLA haplotype and cytokines/receptors
gene polymorphisms have been described
to influence susceptibility to both TB and
malaria. Recently, a polymorphism in the
TLR4 gene has been implicated in
protection against malaria [17,18], while
a variant of the TLR2-4 adapter Mal/
TIRAP can provide protection against
invasive pneumococcal infection, malaria,
and TB [19]. It will therefore be important
to include genetic markers when elucidat-
ing the mechanisms of disease.
Novel Adjuvants and Their Modes of
Action, and Novel Vaccine
Formulations
In view of the fact that reactivity of the
immune system can be altered in circum-
stances of multiple infections, malnutri-
tion, and other conditions, novel vaccine
formulations able to stimulate protective
immunity in states of altered responsive-
ness should be considered. The develop-
ment of safe, potent vaccine adjuvants that
enhance and direct vaccine-specific im-
munity is a crucial issue for all new
vaccines for human use. Recent advances
in immunological research, especially with
regard to innate immunity, has resulted in
a number of potent adjuvant candidates
that can modulate immune responses in a
more controlled and specific manner [20].
However, adjuvants suitable for the devel-
oped world might not give the same result
in populations already exposed to a
number of different NIDs. Thus, develop-
ment of new adjuvants able to promote
broad and sustained immune responses at
systemic and mucosal levels still remains a
major challenge for vaccinology, especially
for people living in developing countries.
Conclusions and Perspectives
Additional research is necessary to
understand the mechanisms of immune
protection and memory during co-infec-
tion with HIV/AIDS, malaria, TB, and
NIDs. The AFRIEND consensus meeting
identified seven key areas with research
gaps, where more attention is needed:
N Correlates of protection
N Mechanisms of infection and immuni-
ty at local sites
N Immunological memory
N Impact of co-infection on the outcome
of HIV/AIDS, malaria, TB, and NIDs
N Impact of non-infectious agents on the
outcome of HIV/AIDS, malaria, TB,
and NIDs
N Host genetics and the outcome of
HIV/AIDS, TB, malaria, and NIDs
N Novel adjuvants and their modes of
action, and novel vaccine formulations
This list is not in order of priority, as all of
these issues shouldbe tackled concomitantly,
in order to obtain effective outcomes. Global
coordination and harmonisation of efforts
therefore are of key importance.
To achieve these goals it will be essential
to put in place a sustainable network
between researchers in disease-endemic
countries and researchers in the developed
world, which together will implement an
integrated immunological research effort
across disciplines and diseases. This needs
to include promotion of high-level training
pathways for African researchers and
sustaining their careers in African institu-
tions. All of this will require consensus and
support both at the political and social
level in low-income countries.
In fact, no scientific achievement, how-
ever relevant, could succeed in being
applied without a proper context of social
acceptability, feasibility, and affordability in
low-income countries. Thus, research and
development of vaccines and therapies for
HIV/AIDS, malaria, TB, and NIDs must
go together with capacity building, local
empowerment, and social awareness.
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